Drug news
FDA extends Berinert (CSL Behring) indication to self administration in HAE attacks
The FDA has approved an extended indication to allow self administration of Berinert (C1 inhibitor concentrate), from CSL Behring, in cases of acute abdominal or facial attacks of Hereditary Angioedema (HAE). This means that there is no need with Berinert for a patient to visit a clinic or hospital to receive the drug intravenously and allows the possibility of quicker treatment. The Berinert indication is also extended by the FDA to laryngeal attacks of HAE which can be life threatening.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins